Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/23166
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartínez-Bonet, M
dc.contributor.authorClemente, M I
dc.contributor.authorSerramía, M J
dc.contributor.authorMoreno, S
dc.contributor.authorMuñoz, E
dc.contributor.authorMuñoz-Fernández, M A
dc.date.accessioned2019-06-28T13:50:25Z-
dc.date.available2019-06-28T13:50:25Z-
dc.date.issued2015-07-01
dc.identifier.citationJ Virus Erad.2015 Jul;(1)3:148-52
dc.identifier.issn2055-6640
dc.identifier.urihttps://hdl.handle.net/20.500.12530/23166-
dc.description.abstractThe limitations to establishing a viral reservoir facilitated by early cART in children could play a critical role in achieving natural control of viral replication upon discontinuation of cART, which could be defined as 'functional cure'. Viral reservoirs could provide a persistent source of recrudescent viraemia after withdrawal of cART, despite temporary remission of HIV-1 infection, as observed in the 'Mississippi baby'. Intensification of cART has been proposed as a strategy to control residual replication and to diminish the reservoirs. The effects of cART intensification with maraviroc persisted after discontinuation of the drug in HIV-1-infected adults. However, in HIV-1-infected children, the emergence of CXCR4-using variants occurs very early, and the use of CCR5 antagonists in these children as intensification therapy may not be the best alternative. New treatments to eradicate HIV-1 are focused on the activation of viral production from latently infected cells to purge and clear HIV-1 reservoirs. This strategy involves the use of a wide range of small molecules called latency-reversing agents (LRAs). Histone deacetylase inhibitors (HDACi) such as givinostat, belinostat and panobinostat, and class I-selective HDACis that include oxamflatin, NCH-51 and romidepsin, are the most advanced in clinical testing for HIV-1 LRAs. Panobinostat and romidepsin show an efficient reactivation profile in J89GFP cells, a lymphocyte HIV-1 latently infected cell line considered a relevant model to study post-integration HIV-1 latency and reactivation. Clinical trials with panobinostat and romidepsin have been performed in children with other pathologies and it could be reasonable to design a clinical trial using these drugs in combination with cART in HIV-1-infected children.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectHIV-latency
dc.subjectHIV-reactivation
dc.subjectpanobinostat
dc.subjectromidepsin
dc.subjectvertically acquired HIV-1 infection
dc.titleImmunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?
dc.typeArtículo
dc.identifier.pubmedID27482406
dc.format.volume1
dc.format.page148-52
dc.identifier.journalJournal of virus eradication
dc.format.number3
dc.identifier.pmcPMC4946732
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC4946732.pdf114.64 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.